Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

How to verify CJC-1295 without DAC purity and batch documentation

A laboratory-focused guide to verifying CJC-1295 without DAC purity and batch documentation, covering analytical identity, purity assessment, and the limits of the published evidence base.

peptides-pro Editorial

CJC-1295 without DAC — also written CJC-1295 no DAC, and referred to in the literature as a growth hormone-releasing hormone (GHRH) analogue — is a synthetic peptide supplied for laboratory research. The evidence block used for this page does not provide a sequence, molecular formula, or molecular weight for the compound, so no such identifiers are stated here. The work indexed in the evidence centres on the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis, the endocrine pathway that GHRH analogues are studied against [2].

Verification of a research-grade peptide rests on three separable questions: whether the material is the intended molecule (identity), how much of the sample is that molecule (purity and measured abundance), and whether the batch is traceable to an analytical record. Published evaluations of the gray-market research peptide supply have found extensive variability in purity and measured abundance across products sold directly to consumers, and have also examined endotoxin burden [3]. Those findings describe the market as a whole; they are not a statement about any individual supplier or lot.

Research Studies

CJC-1295 without DAC and the GH-IGF-1 axis

A review of performance-enhancing peptides encountered in clinical practice and in online self-administration protocols lists CJC-1295 without DAC alongside CJC-1295 with Drug Affinity Complex (DAC) as GHRH analogues, within a broader group that also includes growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin, and ipamorelin, the GH fragment AOD9604, and IGF-1 analogues [2]. The same review frames these agents as unregulated peptides marketed as "research compounds" and intended to modulate the GH-IGF-1 axis [2]. This is a classification and market-survey finding; it does not report a purity specification or an analytical method for verifying the compound.

CJC-1295 without DAC and musculoskeletal recovery models

A scoping review summarised existing peer-reviewed data on six emerging peptides — BPC-157, thymosin beta-4 (TB-500), CJC-1295, MK-677, ipamorelin, and GHK-Cu — for musculoskeletal recovery and enhancement in animal and human models [1]. The review's stated background is that the peptide supplement market has grown rapidly on marketing claims of enhanced performance and accelerated recovery, and that these products are often perceived as low risk despite the absence of efficacy or safety data for many emerging peptides [1]. The review is a summary of the state of the evidence, not a verification protocol.

CJC-1295 without DAC and HIV-associated visceral obesity

A multicentre, randomised, placebo-controlled, double-blind Phase 2 study evaluated CJC 1295 in patients with HIV-associated visceral obesity [7]. Participants were treated for 12 weeks with a 6-week follow-up, and were randomly assigned to low-dose CJC 1295, high-dose CJC 1295, or placebo; the objective was to assess and compare efficacy, pharmacokinetics, safety, and tolerability [7]. This is a human clinical trial record for CJC 1295; the evidence block does not state whether the formulation studied was the DAC or no-DAC variant, and no purity or batch data are reported in the record.

CJC-1295 without DAC and peptide therapeutics in aging

A narrative review of therapeutic peptides in gerontology examined mechanisms, clinical applications, evidence base, and safety profiles of peptides with demonstrated or potential applications in healthy aging and age-related conditions, targeting hallmarks that include metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline [4]. The review's searches covered PubMed, Scopus, and regulatory databases including the FDA and WADA [4]. It is a broad review; it does not supply a batch-verification standard for any single compound.

CJC-1295 without DAC and the gray-market supply

An evaluation of research-grade peptides marketed directly to consumers used a large, publicly available independent testing dataset to assess purity, measured abundance, and endotoxin burden, and to compare cost against compounded and FDA-approved alternatives; the dataset comprised thousands of products [3]. The study's framing is that peptides are a rapidly expanding drug class with a parallel, largely unregulated gray market sold directly to consumers for self-administration [3]. This is the closest evidence in the block to a verification question, and it addresses the market rather than a named supplier.

CJC-1295 without DAC and regulatory status

Reviews of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance describe peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and describe a parallel gray market of unapproved compounds operating largely outside regulatory oversight [5][6]. The same body of work presents pharmacological mechanisms, safety profiles, and regulatory status for prominent approved and unapproved peptides marketed direct to patients [5][6]. Regulatory status is a separate axis from analytical purity: a compound can be analytically correct and still be unapproved.

CJC-1295 without DAC and the limits of the evidence base

Across the reviews indexed here, the recurring finding is that clinical adoption of injectable peptides has outpaced high-quality evidence and regulatory consensus [8], and that use in sport has expanded from anabolic-androgenic steroids toward peptides and peptide analogues marketed as more selective alternatives [10]. Therapeutic peptides in orthopaedics have been described as emerging adjuncts that modulate signalling networks including PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK [11]. None of these sources provides a validated certificate-of-analysis template or an acceptance threshold for a research lot.

CJC-1295 without DAC and what a batch record can and cannot show

The verification question separates into what an analytical record can demonstrate and what it cannot. The table below maps the common documentation elements to the evidence available in this block.

Documentation elementWhat it addressesEvidence in this block
Identity confirmation (mass or sequence)Whether the material is the intended moleculeNo sequence, formula, or molecular weight is given for CJC-1295 without DAC in the evidence block
Purity and measured abundanceHow much of the sample is the target moleculeExtensive variability in purity and measured abundance was found across gray-market research peptides [3]
Endotoxin burdenNon-peptide contaminationEndotoxin burden was among the parameters evaluated in the same dataset [3]
Regulatory statusApproval and oversightUnapproved compounds operate largely outside regulatory oversight [5][6]
Clinical evidence for the compoundWhether human data existA Phase 2 trial record exists for CJC 1295 in HIV-associated visceral obesity [7]; a scoping review covers animal and human models for CJC-1295 among six peptides [1]

Two practical consequences follow from the table. First, a purity figure without an identity determination answers only half the question, and the evidence block supplies no identity specification for this compound. Second, a batch record is a document about a lot, not about a compound class; the market-level variability reported in [3] means that documentation must be read per lot rather than per product name.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp